THE GOLD STANDARD IN THIRD-PARTY CERTIFICATION AND TESTING : +1-800-920-6605, info@bscg.org
Feb 09, 2026
Substances that modify cellular energy metabolism are subject to evaluation by anti-doping authorities and military oversight agencies due to concerns regarding performance enhancement, safety, and fairness. BAM15, a mitochondrial uncoupler that also activates AMPK pathways, is included in global prohibited lists. This inclusion reflects increased scrutiny of research chemicals not approved for human use but found in supplement supply chains.
This post provides an analysis of the regulatory context for BAM15, outlines the biochemical mechanisms underlying its prohibition, and summarizes the testing frameworks established to detect its presence.
BAM15 (PubChem CID: 565708) is a synthetic mitochondrial uncoupler formally known as N5,N6-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine. More specifically, BAM15 is a mitochondrial protonophore uncoupler that interferes with the coupling between electron transport and ATP synthesis in mitochondria. The compound also activates AMP-activated protein kinase (AMPK), a cellular energy sensor. No governmental regulatory health authority has approved BAM15 for human therapeutic use and it remains a research chemical that should not be available for human consumption.
Mitochondrial uncouplers like BAM15 act on the inner mitochondrial membrane by increasing its permeability to protons. Under normal conditions, electron transfer through the electron transport chain creates a proton gradient across this membrane, driving ATP synthesis by ATP synthase. BAM15 enables protons to move back into the mitochondrial matrix without generating ATP, thereby dissipating energy as heat.
This mechanism heightens mitochondrial respiration and energy expenditure. As the proton gradient decreases, electron transport operates with fewer constraints, which increases electron flow and oxygen consumption. Cells compensate for reduced ATP production by elevating substrate oxidation rates.
The resulting metabolic shift is relevant to anti-doping regulation. Increased energy expenditure can theoretically support weight loss and alter body composition. Regulatory agencies consider compounds that affect energy balance at the mitochondrial level as potential performance enhancers, particularly when used alongside physical training or caloric restriction.
AMP-activated protein kinase (AMPK) is a conserved serine/threonine kinase responsible for monitoring cellular energy status. The enzyme activates when cellular AMP:ATP and ADP:ATP ratios increase, signaling reduced energy availability. Activated AMPK promotes catabolic pathways that generate ATP, including enhanced uptake and oxidation of glucose and fatty acids, while suppressing ATP-consuming anabolic pathways such as lipid and protein synthesis.
BAM15 activates AMPK through its mitochondrial uncoupling properties. Research indicates that BAM15-induced uncoupling raises whole-body energy expenditure by increasing skeletal muscle fatty acid flux, mediated by AMPK-dependent suppression of lipogenesis in white adipose tissue.
Substances that stimulate AMPK can influence endurance capacity and metabolic efficiency. These effects have been observed to mirror adaptations resulting from endurance training, leading regulatory bodies to include AMPK activators among metabolic modulators with recognized performance-enhancing potential.
BAM15 was added to the 2026 WADA Prohibited List under section S4.4.1 as an example of an AMP-activated protein kinase activator. This substance is classified as a metabolic modulator and is prohibited at all times, both during and outside of competition.
Drug-testing programs in sports reference the WADA Prohibited List as the primary source for identifying banned substances and methods. Professional leagues, collegiate programs, and military and first-responder drug testing organizations often prohibit a subset of the WADA Prohibited List. The U.S. Department of Defense (DoD) Instruction 1010.16 includes substances banned in sport and categories from the World Anti-Doping Code Prohibited List, including S1 Anabolic Agents, S2 Peptide hormones, growth factors, related substances and mimetics, and S4 Hormone and metabolic modulators.
BAM15, listed under S4 Hormone and metabolic modulators, is included in the WADA-aligned categories central to both sports and military drug testing frameworks. Anti-doping organizations have identified BAM15 in some dietary supplements, although it is not a legal dietary supplement ingredient. BAM15 products illegally sold for human consumption as research chemicals or dietary supplements are growing in popularity representing a growing risk to athletes and regulators. While BAM15 has been added to the WADA Prohibited List it may take more time to be added to the banned substance lists in professional sport that are subject to collective bargaining. The NCAA Banned Substances list prohibits categories including hormone and metabolic modulators and so BAM15 would now be considered as prohibited in the NCAA.
Regulatory caution regarding mitochondrial uncouplers is informed by historical precedent. The compound 2,4-dinitrophenol (DNP), a predecessor to BAM15 that is also banned in sport, was previously used as a weight-loss agent and subsequently banned by the FDA in 1938 due to a high incidence of adverse events. DNP was associated with adverse outcomes such as cataracts, liver failure, agranulocytosis, and fatalities.
Available preclinical data indicate that BAM15 displays a comparatively favorable safety profile. In animal studies, BAM15 administration did not impact body temperature or clinical biomarkers of tissue damage, and minimal adverse effects were documented. Human safety data remain limited, and researchers have not established long-term risk profiles.
Regulatory agencies maintain a cautious position in the absence of robust human data and acknowledge the potential for misuse in performance-enhancing contexts. Research chemicals and unapproved peptides, including substances like BAM15, often lack safety and efficacy studies in humans. Such compounds are not dietary supplements or approved drugs, and they do not require good manufacturing practices or quality control testing for identity or contaminants to the same standards as dietary supplements.
Third-party certification programs provide mechanisms to assess anti-doping risks. The principle of strict liability holds athletes accountable for detected prohibited substances, regardless of intent or source. This increases risk when consuming dietary supplements that may contain undeclared drugs.
Unintentional exposure to prohibited substances in contaminated supplements can result in administrative or disciplinary measures, including separation from military service for affected personnel.
Independent laboratory certification programs enable athletes and service members to limit the risk of inadvertent violations. The BSCG Certified Drug Free program conducts standard screening for over 450 banned substances, including more than 400 drugs present on the WADA Prohibited List, which aligns with military drug testing protocols. Additional recognized third-party banned substance certification providers include Informed Sport and NSF Certified for Sport. The U.S. Military and the mandated Operation Supplement Safety (OPSS) recommend third-party certification to service members to avoid positive drugs tests that may results from supplement use. Similarly, the International Testing Agency that manages drug testing for the Olympics also recommend third-party certification programs like BSCG.
In the BSCG Certified Drug Fre program every finished product lot is tested for over 450 substances, covering more than 400 WADA Prohibited Substances and 50 prescription, over-the-counter, or illicit drugs not exclusively designated for sport. BAM15 has been added to the testing menu to ensure products are not adulterated with BAM15. The program encompasses banned substance detection, Good Manufacturing Practices compliance, and annual product specification verification.
Research into mitochondrial uncouplers is ongoing, with efforts to develop compounds that may provide therapeutic options for obesity, metabolic disorders, and related conditions. Investigations continue to evaluate whether alternatives with improved safety profiles compared to historical compounds such as DNP can be implemented clinically.
The regulatory environment remains active, with periodic updates to the WADA Prohibited List incorporating emerging methods and substances. Recent expansions of the list have included unapproved peptides such as BPC-157 and research chemicals like BAM15. Similarly, the DoD Prohibited Dietary Supplement Ingredients List undergoes quarterly revisions to address new compounds that may attempt to circumvent existing regulation.
Recognized third-party certification plays an established role in supporting compliance as substances such as BAM15 enter the supplement marketplace. Independent testing and certification serve as controls for minimizing the risk of inadvertent exposure to compounds that are now classified as prohibited.
BAM15 is classified as a mitochondrial uncoupler and AMPK activator and is listed on the 2026 WADA Prohibited List under S4 Hormone and metabolic modulators. Its prohibition reflects its potential to alter energy metabolism and its lack of approval for human use.
Anti-doping organizations have reported BAM15 in certain dietary supplements, including products obtained online or supplied without third-party certification. Labeling may not always disclose the presence of BAM15 as it may appear as an adulterant. BAM15 is not legal to sell as a dietary supplement and as a research chemical it may not be sold for human consumption.
Department of Defense Instruction 1010.16 includes substances from the WADA Prohibited List, such as S4 Hormone and metabolic modulators. BAM15 is found within these categories and would be considered prohibited for military personnel subject to drug testing starting in 2026.
Preclinical research indicates that BAM15 may exhibit a more favorable safety profile compared to 2,4-dinitrophenol (DNP), which was banned due to significant adverse effects. Comprehensive human safety data for BAM15 are, however, not yet available.
Participation in third-party certification programs that test for banned substances mitigates the risk of inadvertent exposure. BSCG Certified Drug Free, for example, conducts testing of each product lot for over 450 substances, including those banned by WADA. BAM15 was added to the BSCG testing menu for 2026.
The WADA Prohibited List contains multiple metabolic modulators in category S4. Other substances include GW501516 (Cardarine), meldonium, trimetazidine, and peptides like MOTS-c, which may also activate AMPK pathways.
YouTube Channel
Oliver Catlin Interview
BSCG BLOG
The Hidden Cost of Fair Play: Olympic Drug Testing at the Milan Cortina 2026 Winter Games
The Catlin Perspective blog widget
THE HISTORY OF BSCG